A statement released earlier today by Vetr Inc. about AbbVie Inc (NYSE:ABBV) bumps the target price to $67.75
- Updated: November 27, 2016
Vetr Inc. bumped up the target of AbbVie Inc (NYSE:ABBV) to $67.75 stating a potential upside of 0.12%.
On Monday November 21, 2016, Vetr Inc. released a statement on AbbVie Inc (NYSE:ABBV) bumped up the target price from $0.00 to $67.75 that suggested an upside of 0.12%.
Boasting a price of $60.51, AbbVie Inc (NYSE:ABBV) traded 0.55% higher on the day. With the last close down -3.54% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. AbbVie Inc has recorded a 50-day average of $60.51 and a two hundred day average of $62.73. Volume of trade was down over the average, with 2,942,309 shares of ABBV changing hands under the typical 7,255,480
With a total market value of $0, AbbVie Inc has price-earnings ratio of 16.36 with a one year low of $50.71 and a one year high of $68.12 .
A total of 18 analysts have released a research note on ABBV. Four analysts rating the company a strong buy, ten analysts rating the company a buy, five analysts rating the company a hold, one analyst rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $70.22.
More About AbbVie Inc (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women's health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.